We report an extensive Li ± Fraumeni-like family in which there is an unusual spectrum of tumours at relatively late onset. A germline TP53 splice donor mutation in exon 4 is present in all aected family members available for testing. The mutation abolishes correct splicing of intron 4 and techniques of RT ± PCR have identi®ed three dierent aberrant transcripts from the mutant TP53 allele. Using the yeast functional assay to analyse transcripts in cells from a number of family members with the mutant allele, TP53 appears wild-type. Functional studies have been carried out on cells from patients with and without cancer who carry the germline mutation, and on cells from unaected individuals from the same family who do not carry the mutation. Using a number of functional endpoints known to distinguish between cells carrying mutant or wild-type TP53 alleles, we were unable to discriminate normal (wt/wt) from heterozygous (wt/mut) cells by lymphocyte apoptosis and ®broblast survival following low dose rate ionising radiation exposure. However germline mutation carriers show increased sensitivity to radiation-induced chromosome damage in the G 2 phase of the cell cycle, and decreased transient and permanent G 1 arrest. These studies demonstrate the importance of fully characterising the eects of TP53 germline mutations, and may explain some of the phenotypic features of this family.
Introduction
Li ± Fraumeni syndrome (LFS) is characterized by an unusual familial clustering of tumours including bone and soft-tissue sarcomas, early-onset breast cancer, brain tumours and leukaemias and childhood adrenocortical tumours (Li and Fraumeni, 1969; Li et al., 1988) . The formal criteria for classic LFS are a proband with a sarcoma aged under 45 years, a ®rst degree relative with any cancer under 45 years plus another ®rst or second degree relative with either any cancer under 45 years or a sarcoma at any age (Li et al., 1988) . Some families which fail to meet the criteria for classic LFS have been termed Li ± Fraumeni-like (LFL, Birch et al., 1994) . These are de®ned by a proband with any childhood tumour or sarcoma, brain tumour or adrenocortical tumour under 45 years with a ®rst or second degree relative with any typical LFS tumour at any age, plus another ®rst or second degree relative with any cancer aged under 60 years. Around 70% of classic LFS and 20% of LFL families have been found to have germline mutations of the TP53 gene (Malkin et al., 1990; Birch et al., 1994; Varley et al., 1997a,b) , and these mutations have been found throughout the gene. Many germline mutations described to date involve codons which are known to be vital for normal functioning of p53, whereas others may be inactivating mutations such as deletions or truncating mutations. In families with these types of germline TP53 mutation it is relatively safe to assume that the mutation is causative within the LFS family in which it was found. However in some other cases the signi®cance of the germline TP53 mutation may be less clear-cut, particularly if the mutation has not previously been described or if the consequences of the mutation on transcription or translation are unclear. In such families it is essential to verify that the putative mutation does indeed confer altered function(s) on the transcript or protein product.
We have analysed the TP53 gene in a family which is Li ± Fraumeni-like, and have detected a point mutation aecting the splice donor site of exon 4. The nucleotide involved is not one of the invariant splice-site residues, and is a silent mutation aecting the third position of codon 125 (ACG/gt?ACA/gt, Thr? Thr). Cells from LFS cases have been reported to show abnormal responses to DNA damaging agents such as ionising radiation, including reduced apoptosis (Camplejohn et al., 1995) , permanent G 1 arrest (Williams et al., 1997) and cell killing (Sproston et al., 1996) , and increased chromosome damage in G 2 cells (Parshad et al., 1993; Mitchell and Scott, 1997) . These abnormalities may be a re¯ection of defective genome surveillance in p53-defective cells (Lane, 1992) . We have used these assays to investigate the response of lymphocytes and ®broblasts from this family to examine the functional consequences of this mutation.
Results

Genetic studies
A silent mutation was detected at the third nucleotide position of codon 125 in exon 4 (ACG/gt?ACA/gt, Thr?Thr), and this transition aected the nucleotide immediately adjacent to the splice donor site. The mutation was detected initially in individual III-2, but was con®rmed in IV-4 and IV-7, both of whom were aected with cancer (Table 1) . The mutation was not present in II-3. Blood samples were subsequently obtained from a number of other family members, and their TP53 status determined (Figure 1 ). Of the three family members tested who were aected with cancer, all carried the mutation. Four members unaected at ages 33, 35, 37 and 43 years also had a germline mutation. The remainder of the unaected individuals were wild-type. All of the results presented in this report were obtained as a research project with the full co-operation of the family. In addition, all of the family members have received genetic counselling and many have taken up predictive testing, further details of which will be presented separately (Burn et al, in preparation) .
The mutation aected the third nucleotide of codon 125, and was a silent mutation (Thr?Thr). If the transcript from the mutant TP53 allele was correctly spliced, which is a possibility given that the mutation does not aect one of the invariant residues of the splice donor site, the mutation may have no consequences. It was therefore important to determine whether splicing was aected. We carried out RT ± PCR on mRNA from ®broblasts and lymphocytes from individual III-2 and lymphocytes from IV-4 who both carried the mutation, and ampli®ed a region of the cDNA between exons 2/3 and exon 5 or 5/6. In addition to a product of the expected size, we also detected other products, one around 100 base pairs (bp) smaller than expected, plus two products which were larger than normal. None of these additional products was present in control samples processed in parallel. The RT ± PCR product of the expected size was gel puri®ed and sequenced directly, and there was no detectable mutant sequence. To con®rm this ®nding, cDNA was digested with the restriction endonuclease RsaI, which will cleave the correctly spliced wild-type (exon 4-G/TAC-exon 5), but not mutant (exon 4-A/TAC-exon 5) transcript. There was no residual undigested DNA after extensive overdigestion with RsaI, indicating that the mutant transcript is not spliced at the normal position.
The PCR product which was 100 bp smaller than expected was gel puri®ed and sequenced directly, and represented an incorrectly spliced transcript between a cryptic splice donor site within exon 4 (at position 12099, Genbank accession number X54156), and the splice acceptor of intron 4 (Figure 2 ). The largest additional product was of a size predicted from failure to splice out intron 4, and this was con®rmed by direct sequencing of a PCR fragment ampli®ed from cDNA Table 1 . The genotypes of individuals tested for the germline TP53 mutation are shown using the exon 5/6 reverse primer plus a forward primer within intron 4 (intron 4F2). The third additional PCR product was directly sequenced after ampli®cation with exon 5/6 and intron 4F1 primers. In this transcript, splicing had occurred between a cryptic splice donor site in intron 4 at position 12691 and the splice acceptor of intron 4 (Figure 2 ). The presence of the mutation at the splice donor site within exon 4 therefore prevents normal splicing, and there is no evidence of a correctly spliced product from the mutant allele. In addition, three abnormally spliced products have been detected, one in which there is complete failure to splice intron 4 and two in which cryptic splice donor sites are used. Although we made no attempt to carry out quantitative RT ± PCR, the smaller aberrant product appeared to be approximately as abundant as the wild-type product, the two larger variant products were apparently much less abundant.
Haplotype analysis was carried out on 14 members of family 2635 (8 wt/wt and 6 wt/mut) and 10 members of a family reported by Warneford et al. (1992) with the same mutation as that reported here in family 2635, seven of whom were mutation carriers. Eight markers which map within 1 ± 2 cM of TP53 were typed, including an intragenic pentanucleotide repeat (Futreal et al., 1991) and a very closely linked (CA) n repeat (Jones and Nakamura, 1992). All markers distal to TP53 are shared between the two families, the proximal markers D17S1854 and D17S786 and the (CA) n n repeat alleles are dierent between the two families but common within each family (Figure 3 ). The haplotype analysis is therefore not entirely conclusive, but is consistent with the two families being distantly related with a single recombinant in an earlier generation accounting for the dierence in haplotype in proximal markers.
Functional assays
In cells carrying TP53 mutations, expression of p53 is frequently stabilised and there are alterations to cell cycle checkpoints following DNA damage such as that occurring on exposure to ionising radiation. We have therefore examined the eects of radiation on a variety of phenotypic responses on lymphocytes and fibroblasts from wt/wt and wt/mut members of family 2635.
Lymphocytes We studied the apoptotic response of unstimulated G 0 peripheral blood lymphocytes from nine blood relatives from the family, ®ve with germline mutations and four without ( Table 2 ). The variability in the spontaneous levels of apoptosis (sub G 1 peak, O Gy) is related to the time between phlebotomy and lymphocyte separation (4 ± 6 h), and to uncontrollable eects of transportation of samples. However there was no dierence between the mean values for the two groups (P=0.15) nor was there any dierence between their induced responses (P=0.89). Samples from two other cancer-aected patients with germline TP53 mutations, one from a classic LFS family and the other from an LFL family, showed low levels of induced apoptosis (families 86 and B respectively, see Table 2 ). Lymphocytes from nine individuals were tested for sensitivity to radiation-induced chromosome damage in the G 2 phase of the cell cycle. In our studies of 4100 normal healthy controls, the mean yield was 95 aberrations per 100 cells with over 90% of individuals in the range of 78 ± 110 (updated from Scott et al., 1993) . Using 110 as the cut-o point between a normal and sensitive response, the ®ve family members who were carriers of germline mutations were sensitive (range 122 ± 160), whereas four non-mutation carriers showed aberration yields within the normal range (88 ± 100, Table 3 ). There was no dierence in aberration yield between mutation carriers who are unaected with cancer versus aected individuals.
Fibroblasts We tested whether the germline mutation in family 2635 heterozygotes aected the G 1 checkpoint control by determining the inhibition of incorporation of BrdU after 4 Gy irradiation (Table 4) . We studied eleven strains from blood relatives comprising ®ve wt/ wt individuals with six wt/mut. The results showed a signi®cant dierence between the wt/wt and wt/mut Figure 3 Pedigrees of family 2635 (top) and a partial pedigree adapted from Warneford et al. (1992) . The haplotypes determined for each individual are indicated; the haplotype segregating with the mutation in each family is boxed. The order of the markers shown is indicated in the top right hand corner groups in transient G 1 arrest after irradiation (P=0.006).
Radiation-induced transcriptional activation of the cyclin kinase inhibitor p21 WAF1 occurs as a consequence of enhanced p53 expression and results in permanent G 1 arrest of normal ®broblasts. In TP53 mutation-carrying strains a reduction in permanent G 1 arrest has been observed which correlates with enhanced resistance to low dose rate ionising radiation (Williams et al., 1997) . We tested to see whether the same was true of strains from blood relative members of family 2635. Six wt/wt strains from the family were compared with six wt/mut strains after 4 Gy irradiation (Table 5 ). There was a signi®cant dierence between strains with mutation and those without (P=0.009), but no apparent dierence between strains from cancer aected and unaected individuals (P=0.40) given the small sample sizes.
Clonogenic survival following 0, 3 and 6 Gy low dose rate irradiation was determined for two mutation carrying strains, 178MA and 190MA. From three independent experiments the surviving fractions (mean+standard deviation) following 3 and 6 Gy respectively were 28.6+7.2% and 9.1+2.0% for 178MA and 23.6+11.9% and 6.2+2.8% for 190MA. These values fell within two standard deviations of the corresponding mean values of 12 strains from normal healthy volunteers that we have used to establish the normal response range (Boyle et al., 1998) .
Yeast functional assay A yeast functional assay was carried out on cDNA derived from ®broblast strains established from seven individuals in family 2635, four mutation carriers (III-2, IV-4, IV-8 and IV-10) and three wt/wt (III-1, IV-1 and IV-2). In this assay a wildtype TP53 sequence gives white colonies, and a mutant sequence gives red colonies. All these samples gave results which were clearly within the range of wild-type p53 (under 5% red colonies). Splice acceptor mutation, intron 3 see Varley et al. (1997b) . 
Discussion
The extended Li ± Fraumeni-like family reported here has a splice donor mutation in exon 4 of the TP53 gene. The mutation aects the third nucleotide of codon 125, and is silent at the amino acid level. The mutation does not aect one of the invariant residues at the splice donor site, and it was a possibility that splicing would be unaected. We have shown by RT ± PCR that there is no detectable correctly spliced product, but three abnormal transcripts. In one of these transcripts, there is failure to splice intron 4 which, if translated, would result in an in-frame stop codon 34 amino acids beyond exon 4 (at the equivalent of position 159). There has been a previous report of an identical mutation in an LFL family (Warneford et al., 1992) , and this group also found a transcript corresponding to that with an unspliced intron 4. Warneford et al. (1992) did not however report any additional aberrant products, but they were analysing abnormal transcripts by Northern blotting, and would therefore not have seen the two transcripts in which cryptic splice sites within exon 4 and intron 4 are utilized. Both of these latter transcripts would also result in truncated protein products if translated. Interestingly, the cryptic splice site in exon 4 has previously been identi®ed by Frebourg et al. (1995) when there was germline mutation of the splice donor site of intron 4 (gt?at). Frebourg et al. (1995) also reported splicing between the intron 3 splice donor and the intron 4 acceptor, which we have not seen. The third aberrant transcript that we detected used a cryptic splice site within intron 4, and although this site matches the consensus splice acceptor sequence adequately, there are other candidate cryptic splice acceptor sequences within intron 4 which seem better matches (for example at positions 12786 and 12955).
The ®nding that the mutation in exon 4 does perturb splicing together with the identi®cation of the mutation in three aected patients con®rms that mutation is causative of the cancer predisposition in this family. The spectrum of disease phenotypes is, however, not typical of classic Li ± Fraumeni syndrome, with no sarcomas and no childhood tumours. There are two cases of adenocarcinoma of the lung at relatively young ages (III-11 and III-13, aged 43 and 39 respectively) and a malignant mesothelioma at age 39 (IV-7) with asbestos ®bres at a count of 129,000 ®bres per gram found in lung tissue at post mortem. The latter is particularly interesting in view of some studies suggesting that family history of cancer confers an increased risk of mesothelioma following asbestos exposure (Heineman et al., 1996) . Although these studies failed to reached statistical signi®cance, there was a suggestion that there is an increased risk of mesothelioma with increased numbers of relatives with tumours typical of Li ± Fraumeni syndrome (Heineman et al., 1996) . The mesothelioma identi®ed in individual IV-7 was associated with asbestos exposure, and asbestos ®bres were found in the lung post mortem. A clear cell carcinoma of the ovary was diagnosed in III-10 at age 20. This type of epithelial tumour is relatively uncommon, accounting for around 5 ± 6% of all ovarian epithelial tumours. We have been unable to obtain material on which to carry out mutation testing, but it seems likely that this tumour at such a young age is associated with the presence of a germline TP53 mutation.
Perhaps one of the most intriguing cancers to occur in family 2635 is an adrenal carcinoma at age 45 (III-4). Adrenocortical carcinoma is now a well established component of Li ± Fraumeni syndrome, but this type of tumour occurs almost exclusively in young children. In the family reported by Warneford et al. (1992) , an identical germline TP53 mutation was found, and in many respects the cancer spectrum is similar to that reported here. Although there are two childhood tumours (brain and adrenal) in the former pedigree, there are no cases of sarcoma. In addition, and most strikingly, there is also a case of adult adrenocortical carcinoma (in a woman aged 33 years, Warneford et al., 1991) . To our knowledge, these are the only two cases of adult adrenal carcinoma reported in Li ± Fraumeni syndrome families. The ®nding that the TP53 mutations in the two families are identical together with some striking similarities in tumour spectrum may indicate the ®rst demonstration of a genotype±phenotype correlation between TP53 mutations and cancer type. We have obtained DNA samples from seven wt/mut and three wt/wt blood relatives of the family described by Warneford et al. (1992) , and carried out haplotype analysis using seven microsatellite markers which are closely linked to TP53 plus an intragenic microsatellite repeat. The haplotypes shared by wt/mut individuals within each family are consistent, although alleles proximal to TP53 are not shared between the two families. The data are however consistent with the two families being related with a single recombination event being sucient to account for the observations. If this is the case, the extended family represents the largest Li ± Fraumeni family reported.
A functional assay has been developed which distinguishes between mutant and wild-type TP53 genes based on the ability of p53 to transactivate target genes in yeast (Flaman et al., 1995) . Although this assay is known not to detect all types of TP53 mutation, it was surprising that no mutation was detected in the mutation carriers from family 2635. The assay relies on ampli®cation of cDNA from test material, and gap-repair cloning into a yeast expression vector. The primers used to generate TP53 cDNA¯ank the site of the mutation in family 2635, and also all three of the alternate transcripts. Theoretically therefore all three aberrant products are clonable, and all are expressed at detectable levels in normal cells from family members carrying the mutation. The level of red colonies in the assay was within acceptable levels (under 5%) and indicates that all the products which were cloned were wild-type. It is possible that the two larger aberrant transcripts are present at low levels, and not eciently ampli®ed by the PCR conditions used. The shorter product should, however, be eciently ampli®ed. The reason for the failure to identify the mutant TP53 gene in the yeast assay remains uncertain.
Cells carrying germline mutant TP53 alleles have been shown to exhibit reduced G 1 arrest (Williams et al., 1997) , abnormal apoptotic response (Camplejohn et al., 1995) , increased chromosomal radiosensitivity and increased cellular radioresistance (Sproston et al., 1996) . It is, however, clear from the present study that not all mutant p53s have the same properties. In the family reported here both permanent and transient G 1 arrest are abnormal, and the cells show chromosomal sensitivity to the eects of ionising radiation. However the apoptotic response of lymphocytes is normal, and the cells show no increased cellular radioresistance. Because we have been able to study cells from a number of members of the family with the same genotype, and to compare the endpoints to those in normal individuals from within the same family, we have been able to achieve considerable statistical signi®cance for the data obtained. Clearly the site and type of germline TP53 mutation in¯uences response of cells to the eects of DNA damaging agents, and it is likely that the spectrum of eects may be re¯ected in the phenotype within a family. Further detailed studies of other extended families will be needed to address these questions.
Materials and methods
The pedigree of family 2635 is given in Figure 1 , and the tumour types and ages of onset are presented in Table 1 . The tumours have been veri®ed by examination of pathology reports, and in some cases by pathology review. DNA samples were initially available from lymphocytes from individuals II-3, III-2, IV-4 and IV-7. DNA from III-2 was screened for mutation within TP53 by direct sequencing exon-by-exon from genomic DNA using dye primer cycle sequencing with Amplitaq FS TM (Perkin ± Elmer) and an ABI model 377 automated sequencer (primer sequences available on request). Blood and skin samples were subsequently obtained from other family members, all of whom gave their consent to be tested for the presence of the TP53 mutation, and for the genetic and functional assays described below.
Poly(A) + RNA was isolated from ®broblast cell strains established from individual III-2, and from lymphocytes from individuals III-2 and IV-4. RT ± PCR was initially carried out using primers within exons 2/3 (forward primer) and 5 or 5/6 (reverse primers): Exon 2/3F, TGTAAAACGACGGC-CAGTTATGGAAACTACTTCCTGAAAACA; Exon 5 R, CAGGAAACAGCTATGACC CTTGTTGAGGGCAGGG -GAGTA; Exon 5/6R, CAGGAAACAGCTATGACCGGG-GCCAGACCATCGCTATCTGAG.
Two primers were designed to amplify aberrant splice products, both complementary to sequences within intron 4: Intron 4F1, TGTAAAACGACGGCCAGTATCCCATCA-CACCCTCAGCATC; Intron 4F2, TGTAAAACGACGGC-CAGTAGGAGATGGAGGCTGCAGTGA.
The underlined nucleotides correspond to tail sequences added to the 5' end of the PCR primer sequences to allow dye-primer sequencing of both strands. The exon 2/3F and exon 5/6R primers were designed to span two exons in order to eliminate any possibility of amplifying genomic DNA in the PCR reaction. All sequencing of RT ± PCR products was carried out using cycle sequencing and dye-primers as described.
Haplotype analysis was carried out using seven microsatellite markers closely linked to TP53 (CA n Jones and Nakamura, 1992; D17S796, D17S1796, D17S960, D17S1881, D17S1854, D17S786, Dib et al., 1996) , plus a pentanucleotide (AAAAT) n repeat within the ®rst intron of TP53 (Futreal et al., 1991) . Primary and secondary PCRs were carried out and the products separated on denaturing acrylamide gels as described (Hoggard et al., 1995) .
Messenger RNA from early passage ®broblast cell lines from seven individuals was prepared and cDNA derived. The ability of p53 to transactivate a target gene in yeast was carried out as previously described (Ishioka et al., 1993; Flaman et al., 1995; Lomax et al., 1997) . Both positive and negative controls were processed in parallel (Lomax et al., 1997) .
Radiation-induced apoptosis of peripheral lymphocytes was determined as described by Camplejohn et al. (1995) , and their G 2 chromosomal radiosensitivity according to Scott et al. (1993) with 50 cells scored using coded samples. Fibroblast cell strains were established from thirteen family members using techniques as described in Boyle et al. (1998) . All studies on ®broblasts were carried out at early passage (520 population doublings). Transient and permanent G 1 arrest assays were performed following exposure to 0 and 4 Gy 137 Cs irradiation. Transient G 1 arrest was determined 17 h after irradiation, when irradiated and unirradiated cells were labelled with 10 mM BrdU for 4 h prior to ®xation and staining with FITClabelled anti-BrdU antibodies and propidium iodide. Cell cycle phases were determined by FACS analysis as described (Kuerbitz et al., 1992) . Permanent G 1 arrest was determined autoradiographically from ®ve measurements of the accumulation of [ 3 H]thymidine taken over the interval 60 ± 120 h post-irradiation (Williams et al., 1997) . Cell survivals were measured by clonogenic assays following exposure to 0, 3 and 6 Gy low dose rate ionising radiation (Boyle et al., 1998) . Triplicate plates were scored at each dose and the experiments were repeated on three separate occasions.
t-tests or Mann ± Whitney U tests were applied using the SPSS statistical package. The availability of samples from multiple members of the same family with both wt/wt and wt/mut TP53 status allowed comparison of the eects of the mutation using the aggregated data of single determinations on each individual.
